Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP policies and guidelines news

Show

From To
Most PrEP users in Berlin obtained it from informal channels

Over half of men who have sex with men (MSM) living in Berlin who were using HIV pre-exposure prophylaxis (PrEP) accessed it through informal sources, without consistent

Published
02 October 2018
By
Krishen Samuel
US doctors’ organisation endorses event-based PrEP for the first time

For the first time, a US-based professional HIV body has published guidelines endorsing event-based or so-called ‘on-demand’ pre-exposure prophylaxis (PrEP) as an alternative to daily dosing. The International

Published
19 September 2018
By
Gus Cairns
UK HIV drugs bill may reduce following court ruling - implications for PrEP

A ruling today from the European Court of Justice (ECJ) suggests that Gilead’s patent for Truvada (the drug used to treat many people living with HIV, and the drug used for PrEP) may be under threat.

Published
25 July 2018
From
National AIDS Trust
Pharma giant withdraws challenge to generic HIV anti-retroviral drug

Gilead has dropped its appeal against the High Court’s refusal to grant an injunction against generic manufacturers.

Published
21 December 2017
From
Irish Times
Gilead loss of generic HIV drug battle a boost for gay community

Published
09 November 2017
From
The Irish Times
Gilead Continues To Block Ireland From Sourcing Generic Truvada

Gilead Sciences, the company that supplies Ireland with the drug Truvada, will have a full court hearing in mid-October to determine whether the Irish Health and Safety Executive (HSE) can source a generic analogue of the drug from the pharmaceutical giant’s competitors. In July, GCN reported that Gilead was taking legal action to stop the HSE from securing generic drug from Actavis and Mylan, the company’s competitors, for the purposes of HIV prevention as PrEP.

Published
16 October 2017
From
Gay Community News
Generic PrEP in France and Scotland challenges access across the UK

The issue of drug procurement and pricing is complex but it is difficult to see how different patents should apply within Europe, and especially not within the UK.

Published
08 September 2017
From
HIV i-Base
Did HIV Pharma “Pay to Delay” Generic Truvada?

AIDS activists urge the N.Y. attorney general to investigate possible antitrust violations regarding the HIV med used as PrEP.

Published
04 September 2017
From
Poz
Mylan to Provide Generic Truvada for U.K. Trial

The NHS confirmed Thursday that Mylan had won the drug procurement process for a three-year-long implementation trial for pre-exposure prophylaxis, or PrEP, which is used to prevent HIV infection.

Published
03 August 2017
From
Wall Street Journal
Surprise FDA Approval of Generic Truvada Is a 'Wakeup Call' for Activists

The surprise approval of generic Truvada (tenofovir disoproxil fumarate and emtricitabine) by the U.S. Food and Drug Administration (FDA) on June 9 left patients, advocates and doctors scrambling to understand exactly when the generic will become available and how much it will cost.

Published
07 July 2017
From
The Body

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.